centanafadine

Centanafadine is Otsuka's investigational ADHD pill that blocks the reuptake of three neurotransmitters at once: norepinephrine, dopamine, and serotonin. The FDA accepted its New Drug Application (NDA, the formal submission package requesting approval) and granted Priority Review on January 27, 2026, covering children, adolescents, and adults, with a PDUFA target action date (the statutory date by which FDA must complete its review under the Prescription Drug User Fee Act) of July 24, 2026 [1]. If approved, it would be the first triple monoamine reuptake inhibitor for ADHD. Whether DEA schedules it as a controlled substance has not been publicly disclosed by Otsuka, but the pharmacology (NET-dominant, low dopamine engagement) is consistent with a non-scheduled outcome [2]. Non-scheduled status matters commercially because branded non-stimulants compete in a market where Adderall shortages and DEA scheduling friction push prescribers away from stimulants. Otsuka already runs one of the larger psychiatry sales forces in the US through Abilify and Rexulti, so launch infrastructure is in place. Four key Phase 3 trials in adults, adolescents, and children all read out positive on standard ADHD symptom scales [1][3][8]. This is now a regulatory and commercial story, not a Phase 3 risk story.

Novel small molecule, never approved anywhere. The asset originated as EB-1020 at Neurovance and came to Otsuka via the 2017 Neurovance acquisition. The NDA was accepted by FDA on January 27, 2026, with PDUFA July 24, 2026, and was granted Priority Review (6-month review clock instead of the standard 10-month) [1]. No breakthrough therapy designation has been disclosed publicly. The single NDA covers ADHD in pediatric (ages 6-12), adolescent (13-17), and adult populations, which is structurally unusual; most psychiatry sponsors split filings by age group. Otsuka has also run centanafadine through Phase 2 in major depressive disorder as monotherapy and SSRI adjunct (NCT05536414, n=337) [4], and a completed Phase 3b ADHD-with-comorbid-anxiety trial (NCT06973577, n=315) [5], positioning the compound as a CNS platform if the ADHD launch lands. Otsuka commercializes Rexulti for Alzheimer agitation and Abilify Maintena for schizophrenia, so a triple monoamine asset slots into an existing psychiatric salesforce. Abilify lost exclusivity years ago and Rexulti faces eventual generics; centanafadine is part of how Otsuka extends its post-Abilify CNS franchise. Composition-of-matter and formulation patent expiry dates for centanafadine are not publicly summarized in a single authoritative source; expect detail in Otsuka's eventual Orange Book listing on approval.

Most ADHD drugs hit either dopamine and norepinephrine together (stimulants like Adderall, Vyvanse, methylphenidate) or norepinephrine alone (Strattera, Qelbree). Centanafadine blocks the reuptake transporters for all three monoamines: norepinephrine (NET), dopamine (DAT), and serotonin (SERT) [2][6]. Reuptake transporters act like molecular vacuum cleaners that pull neurotransmitter back into the neuron after release. Block them, and more signal stays in the synapse for longer, which is the same trick SSRIs use for depression. The interesting part is the ratio. A Phase 1 PET occupancy study in healthy adult males (Matuskey et al. 2023) measured the in vivo affinity ratios as NET/DAT ~11.9 and NET/SERT ~13.3, with DAT/SERT ~1.1, meaning the compound is strongly NET-dominant with DAT and SERT engagement essentially equivalent to each other and roughly 12-fold weaker than NET [2]. At the 400 mg total daily dose, peak NET occupancy reached 64% (±7%), while at the higher plasma concentrations observed in dosing, DAT occupancy was estimated near 47% and SERT near 44%. Stimulants flood the synapse with dopamine in a way that creates reward and abuse liability, which is why they are DEA-scheduled. Centanafadine's NET-dominant, low-DAT profile is the design rationale for cognitive benefit without the high. The serotonin piece may also dampen anxiety and emotional dysregulation that often ride along with ADHD, which is why Otsuka ran the comorbid-anxiety Phase 3b [5]. NET and DAT blockade for ADHD is well-validated by atomoxetine and methylphenidate. The triple-reuptake combination is the novel piece; prior triple reuptake inhibitors in depression (amitifadine/EB-1010, DOV 21,947) failed Phase 2/3 in MDD on efficacy and tolerability grounds, but for indication-specific reasons that do not directly bear on the ADHD case. Phase 3 efficacy on AISRS (adults) and ADHD-RS-5 (pediatric) scales says the biology translated [3][8].

The NDA package rests on four key Phase 3 trials covering adults, adolescents, and children, plus a long-term safety study [1]. The adult registration package is two Phase 3 monotherapy trials (Otsuka 405 and 406 series) that read out positive in 2022 on the Adult ADHD Investigator Symptom Rating Scale (AISRS, a clinician-rated scale that scores the 18 DSM-5 ADHD symptoms on severity) at 200 mg and 400 mg once-daily extended-release. The pediatric package includes two short-term efficacy trials in children (ages 6-12) and adolescents (13-17), plus a long-term safety study (NCT05279313) that enrolled 680 children and adolescents specifically to characterize chronic dosing tolerability [7][8]. Endpoints are FDA-acceptable symptom scales: ADHD-RS-5 (the 18-item ADHD Rating Scale, fifth edition, parent or clinician-rated) in pediatrics and AISRS in adults, both versus placebo. No active comparator arm against stimulants or atomoxetine, which is typical for ADHD approval but leaves head-to-head efficacy questions unanswered for payer negotiations. The Phase 3b ADHD-with-anxiety trial (NCT06973577) enrolled 315 patients measuring AISRS change and completed in 2025 [5]. A Phase 1 drug-drug interaction study with stimulants (NCT07314333) checked blood pressure effects of co-administration, presumably to support label language around use alongside or as a switch from stimulants [9]. The published meta-analysis pooling randomized centanafadine trials reports statistically significant improvement on symptom scales versus placebo with a tolerability profile favoring lower discontinuation than stimulants [3]. Specific placebo-corrected effect sizes are not summarized in a single public document, but the literature describes them as modest and consistent with other non-stimulants (typically several points on ADHD-RS-5 versus placebo, smaller than stimulant deltas).

The model gives this drug a 31% chance of eventually being approved. That number starts from the historical approval rate for Phase 3 drugs in this area, which is about 51%, then adjusts based on ten specific facts about the trial and its sponsor. The estimate is helped by the trial's non-randomized design, but pulled down by the sponsor's thin approval record, the drug's few secondary endpoints, and weak earlier-phase results. The remaining facts were close to average, so they left the final estimate near where the base rate started.

Efficacy risk is largely retired. Phase 3 trials were positive on the FDA-acceptable scales [3][8]. The lingering question is effect size versus stimulants, which the trials did not directly measure. If the placebo-corrected delta on ADHD-RS is modest, prescribers used to stimulant response magnitudes may not switch patients, hurting commercial uptake even with approval. Safety risk centers on cardiovascular effects. Norepinephrine reuptake blockade raises blood pressure and heart rate, which is why the long-term pediatric safety trial existed (NCT05279313) [7]. The label will carry BP and HR monitoring language. Serotonin reuptake adds risk of serotonin syndrome with concomitant SSRIs and SNRIs, relevant because ADHD patients are often comedicated for depression or anxiety; expect a label warning to that effect. Consistent with the labels for atomoxetine (Strattera) and viloxazine (Qelbree), expect a pediatric suicidality black box on centanafadine. FDA has applied this warning to non-stimulant ADHD drugs as a class based on pharmacovigilance signals in ADHD populations, not on serotonin mechanism per se. Regulatory risk: Priority Review compresses the FDA review window but does not eliminate the possibility of an advisory committee on a novel mechanism. Commercial risk is the real story. Qelbree (viloxazine, Supernus) launched in 2021 as a non-stimulant; Supernus reported approximately $231M in Qelbree net sales in 2024 according to its public filings, growing roughly 72% year-over-year, which is the recent reference for what a branded non-stimulant launch can build to in three to four years [10]. Strattera went generic. Vyvanse is generic. Centanafadine at branded specialty pricing without head-to-head superiority data will face payer pushback and step-therapy requirements behind generic stimulants and atomoxetine. Otsuka has not publicly disclosed a DEA scheduling determination; the assumption that centanafadine launches non-scheduled is consistent with the NET-dominant, low-DAT pharmacology but remains assumption rather than confirmed fact until DEA acts.

Watch this. The July 24, 2026 PDUFA is a fixed binary event roughly one month away, and approval is more likely than not given the Phase 3 readouts, NDA acceptance, and Priority Review designation [1]. The specific signals worth tracking are not whether but how: which age groups get approved, what doses make the label, what warnings attach, and whether DEA schedules it (presumably no, but a non-scheduled label is the key commercial wedge against stimulants). After approval, the next data points that matter are Otsuka's Q4 2026 and Q1 2027 earnings calls. Watch prescription volume ramp, payer access, and whether Otsuka discloses formulary wins. The MDD Phase 2 readout (NCT05536414) and the ADHD-with-anxiety Phase 3b (NCT06973577) define whether centanafadine becomes a single-indication asset or a CNS platform extending Otsuka's psychiatry franchise as Abilify generics continue eroding and Rexulti faces its own LOE (loss of exclusivity, the date when patents expire and generics can enter) clock [4][5]. Connect this to the company story: Otsuka needs a new psychiatry growth driver. If centanafadine launches well and the MDD data supports a Phase 3, the asset carries the franchise into the 2030s. If launch is slow or the label restricts age groups, Otsuka's CNS revenue gap widens. Check back late July 2026 for the FDA decision and February 2027 for first full quarter launch metrics.